急性淋巴细胞白血病患者化疗相关性糖尿病的特点。
Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients.
机构信息
Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Institute of Hematology, Zhejiang University, Hangzhou 310003, China.
出版信息
J Zhejiang Univ Sci B. 2020;21(9):740-744. doi: 10.1631/jzus.B1900719.
Acute lymphocytic leukemia (ALL) is one of the most common malignancies, especially in young people. Combination chemotherapy for ALL typically includes corticosteroids (Kantarjian et al., 2000). Hyperglycemia is a well-recognized complication of corticosteroids, and chemotherapy-induced diabetes (CID) is not uncommon (27.5%-37.0%) during the treatment of ALL (Hsu et al., 2002; Weiser et al., 2004; Alves et al., 2007). Besides the effect of corticosteroids, potential factors triggering hyperglycemia in ALL also include direct infiltration of the pancreas by leukemia cells and β cell dysfunction induced by chemotherapeutic agents such as L-asparagine (Mohn et al., 2004).
急性淋巴细胞白血病（ALL）是最常见的恶性肿瘤之一，尤其在年轻人中。ALL 的联合化疗通常包括皮质类固醇（Kantarjian 等人，2000）。高血糖是皮质类固醇的一种公认并发症，在 ALL 的治疗过程中，化疗诱导的糖尿病（CID）并不少见（27.5%-37.0%）（Hsu 等人，2002 年；Weiser 等人，2004 年；Alves 等人，2007 年）。除了皮质类固醇的作用外，导致 ALL 患者高血糖的潜在因素还包括白血病细胞对胰腺的直接浸润，以及化疗药物如 L-天冬酰胺引起的β细胞功能障碍（Mohn 等人，2004 年）。
Zotero 插件